Brought to you by 
Cephalon completes $300mm convertible debt offering
11 Feb 2002
Executive Summary
Cephalon (CNS therapeutics) has completed a private placement of $300mm in subordinated notes due in 2006, with an annual interest rate of 5.25%, convertible into Cephalon common at $74 per share to institutional investors.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon completes $300mm convertible debt offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice